Evidence map›Paper›PMID 21323962›Full record

ArticleHistopathology2011

HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH).

James E Boers, Harriëtte Meeuwissen, Natalie Methorst

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Histopathology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
9.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
  4. Article
  5. HER2, NF-Disease markers · 2019
    Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Gastric biomarkers: a global review.World journal of surgical oncology · 2016
    Review
  11. HER2 testing in gastric cancer: An update.World journal of gastroenterology · 2016
    Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Expression of asialoglycoprotein receptor 1 in human hepatocellular carcinoma.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2013
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

James E BoersDepartment of Pathology, Isala klinieken, Zwolle, the Netherlands. j.e.boers@isala.nl/j.e.boers@me.com
Harriëtte Meeuwissen
Natalie Methorst
Isala · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsHER2 gene amplification has been detected in 10-20% of gastric adenocarcinomas. In view of the recently demonstrated clinical benefit of the anti-human epidermal growth factor receptor 2 (HER2) drug trastuzumab in the treatment of advanced gastric cancer, reliable HER2 testing is of key importance. The aim of this study was to examine HER2 status in gastro-oesophageal adenocarcinomas comparing SP3 and 4B5 immunohistochemistry (IHC) with dual probe HER2 [fluorescence in situ hybridization (FISH) and silver in situ hybridization (SISH)]. METHODS AND

resultsIHC and SISH were carried out on biopsy specimens of 146 patients with adenocarcinomas of the oesophagus and stomach. All SP3-IHC-positive cases and 91% of 4B5-IHC-positive cases were amplified. Sensitivity of SP3-IHC-positivity and 4B5-IHC-positivity for amplification was 77% and 96%, respectively. Results of FISH performed in 42 cases were identical to SISH. Amplification was heterogeneous in 73% of the adenocarcinomas; 24% of the oesophago-gastric carcinomas and 7% of distal stomach tumours were amplified.

conclusionsHER2-positivity is present in a significant proportion of oesophago-gastric adenocarcinomas (24%), but at a lower rate in the distal stomach (7%). Sensitivity for amplification is higher with 4B5 IHC than with SP3. FISH and SISH yield identical results, but assessment is much easier with SISH. Our findings provide important guidance for HER2-testing in gastro-oesophageal adenocarcinomas for patients in whom anti-HER2 treatment is considered.

Indexed as

AdenocarcinomaAntibodies, MonoclonalErb-b2 Receptor Tyrosine KinasesEsophageal NeoplasmsGene AmplificationHumansImmunohistochemistryIn Situ HybridizationIn Situ Hybridization, FluorescenceSilverStomach NeoplasmsAntibodies, MonoclonalERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesSilver

Identifiers

PMID21323962
PMCPMC3085073
OpenAlexW1487117163

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.